Prevention of stroke in patients with chronic coronary syndromes or peripheral arterial disease

William A. E. Parker, Diana A. Gorog, Tobias Geisler, Gemma Vilahur, Dirk Sibbing, Bianca Rocca, and Robert F. Storey

1Cardiovascular Research Unit, Department of Infection, Immunity & Cardiovascular Disease, University of Sheffield, Beech Hill Road, Sheffield, S10 2RX, UK
2Department of Medicine, National Heart & Lung Institute, Imperial College, London, UK
3Postgraduate Medical School, University of Hertfordshire, Hatfield, UK
4Department of Cardiology and Angiology, University of Tübingen, Tübingen, Germany
5Cardiovascular ICC Program, Research Institute-Hospital de la Santa Creu i Sant Pau, IIB-Sant Pau, Barcelona, Spain
6Centro de Investigación Biomédica en Red Cardiovascular (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain
7Privatklinik Lauterbacher Mühle am Ostersee, Iffeldorf, München, Germany
8Ludwig-Maximilians-Universität, München, Germany
9Medizinische Klinik und Poliklinik I, Campus Großhadern, München, Germany and
10Department of Pharmacology, Catholic University School of Medicine, Rome, Italy

KEYWORDS
Stroke; Myocardial infarction; Coronary artery disease; Peripheral arterial disease; Antiplatelet drugs; Anticoagulant drugs; Aspirin; Clopidogrel; Ticagrelor; rivaroxaban

Stroke is a common and devastating condition caused by atherothrombosis, thromboembolism, or haemorrhage. Patients with chronic coronary syndromes (CCS) or peripheral artery disease (PAD) are at increased risk of stroke because of shared pathophysiological mechanisms and risk-factor profiles. A range of pharmacological and non-pharmacological strategies can help to reduce stroke risk in these groups. Antithrombotic therapy reduces the risk of major adverse cardiovascular events, including ischaemic stroke, but increases the incidence of haemorrhagic stroke. Nevertheless, the net clinical benefits mean antithrombotic therapy is recommended in those with CCS or symptomatic PAD. Whilst single antiplatelet therapy is recommended as chronic treatment, dual antiplatelet therapy should be considered for those with CCS with prior myocardial infarction at high ischaemic but low bleeding risk. Similarly, dual antithrombotic therapy with aspirin and very-low-dose rivaroxaban is an alternative in CCS, as well as in symptomatic PAD. Full-dose anticoagulation should always be considered in those with CCS/PAD and atrial fibrillation. Unless ischaemic risk is particularly high, antiplatelet therapy should not generally be added to full-dose anticoagulation. Optimization of blood pressure, low-density lipoprotein levels, glycaemic control, and lifestyle characteristics may also reduce stroke risk. Overall, a multifaceted approach is essential to best prevent stroke in patients with CCS/PAD.

Introduction
Significant mortality and morbidity arise from complications of either chronic coronary syndromes (CCS), encompassing symptomatic or asymptomatic coronary artery disease (CAD) with or without a history of acute coronary syndrome (ACS), or peripheral artery disease (PAD), including lower extremity arterial disease (LEAD), and carotid artery stenosis. Those with CCS/PAD are at increased risk of acute atherothrombotic events, including ACS,
[myocardial infarction (MI) or unstable angina (UA)], acute limb ischaemia (ALI), and acute stroke.1,2

There are three main mechanisms of stroke (Figure 1). Patients with CCS/PAD may be at particular risk of stroke because of shared underlying disease processes and risk-factor profiles (Figure 2). Pathological mechanisms of atherothrombotic stroke are shared with most ACS and ALI, involving atheromatous plaque formation, rupture, and/or erosion, triggering thrombosis via activation of platelets and the coagulation cascade.3 The processes and risk factors leading to cardioembolic stroke, on the other hand, have less in common with CCS and PAD. Compared to atherothrombotic stroke in which platelets and adhesive molecules are central, activation of the coagulation cascade primarily drives cardiac thromboembolism in a setting of stasis and inflammation, most notably from the left atrial appendage in patients with atrial fibrillation (AF), although there are other possible sources (Figure 1).4

In this review, we present pharmacological strategies to prevent stroke in patients with CCS/PAD. Similarities in pathogenetic mechanisms can provide insights into therapies, and we explore clinical data supporting or refuting these. Whilst focusing on ischaemic stroke, preventing haemorrhagic stroke is also important, particularly since some treatments of CCS, PAD, and acute stroke may increase its incidence.

Antithrombotic therapy

Antiplatelet therapy

As platelet activation is the central process in acute complications of CCS and PAD, there is a clear rationale for the use of antiplatelet therapy (APT) in these groups. Similarly, those treated by coronary or peripheral artery stenting are at risk of platelet-mediated stent thrombosis.2

Use of single antiplatelet therapy

Numerous randomized controlled trials (RCTs) have established the benefits of APT in patients with CCS/PAD. Single antiplatelet therapy (SAPT) with aspirin, which inhibits platelet cyclooxygenase-1-mediated TXA2 synthesis,5 has proven efficacy in the prevention of major adverse cardiovascular events (MACE, defined as cardiovascular (CV) death, non-fatal MI, or non-fatal stroke) in high-risk patients. A meta-analysis by the Antithrombotic Trialists’ Collaboration, including individual data from 135 000 patients with pre-existing CV disease, showed clear benefit, mainly with aspirin alone, in reducing MACE by around 25% [relative risk reduction (RRR): those with prior MI = 21%, \(P < 0.0001\); other-CAD = 37%, \(P < 0.0001\); PAD 23%, \(P = 0.004\)].6 This included a significant reduction in non-fatal ischaemic stroke (3.5% to 2.6%, RRR = 25%). Increases in haemorrhagic stroke risk were offset by a non-significant reduction in total stroke risk of 21%. Similarly, a more recent meta-analysis has provided further insight, suggesting that aspirin significantly reduces the risk of large-artery atherothrombotic stroke [odds ratio = 0.87, 95% confidence interval (CI) 0.76–1.00; \(P = 0.046\)], but not small vessel occlusion or cardioembolism.7

Platelet P2Y12 receptor inhibitors have also been tested in CCS/PAD (Tables 1 and 2, Figure 3).16 P2Y12, its natural ligand being adenosine diphosphate, plays a central role in the amplification of platelet activation. Three orally-active P2Y12 inhibitors have been marketed. The
thienopyridines clopidogrel and prasugrel are pro-drugs whose active metabolites irreversibly inhibit P2Y12. Both require metabolic activation, which is predictably consistent and effective for prasugrel whereas, for clopidogrel, there is significant inter-individual variability and around one-third of the population are poor responders. The cyclopentyl-triazolopyrimidine ticagrelor is a directly-acting, reversibly-binding P2Y12 inhibitor and inverse agonist. Ticagrelor and prasugrel are more potent than clopidogrel with less inter-individual variability.

In the Clopidogrel vs. Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study, P2Y12 inhibitor SAPT with clopidogrel 75 milligrams (mg) once daily was compared with aspirin 325 mg once daily in patients with CCS and PAD (Tables 1 and 2). There was a modest RRR in MACE but a suggestion of greater efficacy in PAD patients, leading to recommendations that, if SAPT is indicated in symptomatic PAD, clopidogrel may be preferred to aspirin. In patients with asymptomatic LEAD, there is no clear evidence that SAPT with aspirin prevents vascular events, including stroke, although studies have been small and underpowered (Supplementary material online).

It has been hypothesized that more potent and consistent P2Y12 inhibitors than clopidogrel might offer better protection against MACE. The Examining Use of ticagrelor In peripheral artery disease (EUCLID) trial randomized patients with symptomatic PAD to ticagrelor or clopidogrel (Table 2). Over a median follow-up of 30 months, there was no significant difference in MACE, although there was a significant reduction in the secondary endpoint of ischemic stroke with ticagrelor, meaning that, for stroke prevention in PAD, ticagrelor may offer some benefit over clopidogrel, although ticagrelor monotherapy is not approved in PAD.

In The Acute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial, ticagrelor monotherapy was not superior to aspirin monotherapy in 13 199 patients with non-severe ischemic stroke or high-risk transient ischaemic attack, with similar bleeding profile. Around 12% of the trial population had CAD or previous MI and similarly in these patients there was no superiority of ticagrelor vs. aspirin (P = 0.89).

Use of dual antiplatelet therapy
In ACS, aspirin plus a P2Y12 inhibitor [dual antiplatelet therapy (DAPT)] has proven benefits over aspirin alone in preventing MACE. When used in DAPT, ticagrelor, in all ACS,
Table 1. Primary and stroke outcomes of total study groups from key RCTs comparing regimens of P2Y12 inhibitors or rivaroxaban with aspirin monotherapy in patients with CCS/PAD in sinus rhythm.

| Short name (year published) | Population | Experimental group(s) | Comparator | Primary endpoint | Key safety endpoint | Ischaemic stroke | Haemorrhagic stroke | Total stroke |
|-----------------------------|------------|-----------------------|------------|-----------------|---------------------|-----------------|-----------------|-------------|
| CAPRIE (1996)               | 19 185 patients with atherosclerotic CV disease (including 6302 with prior MI, 6452 with PAD) | Clopidogrel 75 mg once daily | Aspirin 325 mg once daily | MI, ischaemic stroke, or CV death: 5.32% vs. 5.83%, RRR 8.7% (0.3–16.5), \( P = 0.043 \). Subgroup analysis: only significant difference in those with PAD | Severe bleeding: 1.38% vs. 1.55% (\( P \geq 0.05 \)) | NR | NR | 438 events vs. 432 |
| CHARISMA (2006)             | 15 603 patients with clinically evident CV disease or multiple risk factors (48% with CCS, 23% with symptomatic PAD) | Clopidogrel 75 mg once daily + aspirin 75-162 mg once daily | Aspirin 75-162 mg once daily | CV death, MI, or stroke: 6.8% vs. 7.3%, HR = 0.93 [0.83–1.05], \( P = 0.22 \) | GUSTO severe bleeding: 1.7% vs. 1.3%, HR = 1.25 [0.97–1.61], \( P = 0.09 \) | 1.7% vs. 2.1%, HR = 0.81 [0.64–1.02], \( P = 0.07 \) | 1.9% vs. 2.4%, HR = 0.79 [0.64–0.98], \( P = 0.03 \) |
| PEGASUS TIMI 54 (2015)      | 21 162 patients aged \( \geq 50 \) years with a history of spontaneous MI 1-3 years prior to enrolment AND at least one additional atherothrombosis risk factor \(^a\) | Ticagrelor 60-mg or 90-mg twice daily \(^b\) plus aspirin 75-150-mg once daily | Aspirin 75-150-mg once daily | CV death, MI or stroke: 7.77% vs. 9.04%, HR = 0.84 [0.74–0.95], \( P = 0.008 \) | TIMI major bleeding: HR = 2.32 [1.68–3.21], \( P < 0.001 \) | 1.28% vs. 1.65%, HR = 0.76 [0.56–1.02], \( P = 0.06 \) | 0.19% vs. 0.19%, HR = 0.75 [0.57–0.98], \( P = 0.03 \) |
| DAPT (2014)                 | 9961 patients 12 months post-PCI (26% for MI) followed up for a further 18 months | Aspirin 75-162 mg once daily + continued thienopyridine (65% clopidogrel 75 mg once daily, 35% prasugrel 5 or 10 mg once daily adjusted to weight) | Aspirin 75-162 mg once daily | Stent thrombosis: 0.4% vs. 1.4%, HR = 0.29 [0.17–0.48], \( P < 0.001 \); CV death, MI, or stroke: 4.3% vs. 5.9%, HR = 0.71 [0.59–0.85], \( P < 0.001 \) | GUSTO Moderate or severe bleeding: 2.5% vs. 1.6%, HR = 1.61 [1.21 to 2.16], \( P = 0.001 \) | 0.5% vs. 0.7%, HR = 0.68 [0.40–1.17], \( P = 0.16 \) | 0.3% vs. 0.2%, HR = 1.20 [0.50 to 2.91], \( P = 0.68 \) | 0.8% vs. 0.9%, HR = 0.80 [0.51–1.25], \( P = 0.32 \) |
| THEMIS (2019)               | 19 220 patients with T2DM and CCS but no history of MI | Aspirin 75-150 mg once daily + ticagrelor 60 mg twice daily (reduced from 90 mg early in the trial) | Aspirin 75-150 mg once daily | CV death, MI, or stroke: 7.7% vs. 8.5%, HR = 0.90 [0.81–0.99], \( P = 0.04 \) | TIMI major bleeding: HR = 2.32 [1.82–2.94], \( P = 0.005 \) | 1.6% vs. 2.0%, HR = 0.80 [0.64–0.99], \( P < 0.001 \) | 1.9% vs. 2.3%, HR = 0.82 [0.67–0.99] |

(continued)
### Table 1. Continued

| Short name (year published) | Population | Experimental group(s) | Comparator | Primary endpoint | Key safety endpoint | Ischaemic stroke | Haemorrhagic stroke | Total stroke |
|----------------------------|------------|------------------------|------------|-----------------|---------------------|------------------|---------------------|-------------|
| COMPASS (2017)           | 27 395 with CCS (91%) + additional risk factors if <65 years old or symptomatic PAD (27%) | Aspirin 100 mg once daily + rivaroxaban 2.5 mg twice daily; or, | Aspirin 100 mg once daily | CV death, MI, or stroke: 4.1% vs. 5.4%, HR = 0.76 [0.66-0.86], P < 0.001; Modified ISTH major bleeding: 3.1% vs. 1.9%, HR = 1.70 [1.40-2.05], P < 0.001; | 0.7% vs. 1.4%, HR = 0.51 [0.38-0.68], P < 0.001; | 0.3% vs. 0.1%, HR = 2.70 [1.31-5.58], P = 0.005 | 0.9% vs. 1.6%, HR = 0.58 [0.44-0.76], P < 0.001 | 0.9% vs. 1.6%, HR = 0.58 [0.44-0.76], P < 0.001 |
|                            |            |                        |           |                 |                     |                  |                     |             |
|                            |            |                        | Rivaroxaban 5-mg twice daily | 4.9% vs. 5.4%, HR = 0.90 [0.79-1.03], P = 0.12 | 2.8% vs. 1.9%, HR = 1.51 [1.25-1.84], P < 0.001; | 1.0% vs. 1.4%, HR = 0.69 [0.53-0.90], P = 0.006 | 0.3% vs. 0.1%, HR = 2.70 [1.31-5.58], P = 0.005 | 1.3% vs. 1.6%, HR = 0.82 [0.65-1.05], P = 0.12 |

---

aData shown are for ticagrelor 60-mg twice daily vs. placebo; *P*-value of <0.026 denotes statistical significance.

bAge ≥65 years, diabetes mellitus, second prior MI, multivessel CAD or chronic non-endstage renal disease.

cDocumentation of atherosclerosis involving at least two vascular beds or to have at least two additional risk factors (current smoking, diabetes mellitus, an estimated glomerular filtration rate [GFR] <60 mL/min, heart failure, or non-lacunar ischaemic stroke ≥1 month earlier).

Values in square brackets represent 95% confidence intervals.

CCS, chronic coronary syndrome; CV, cardiovascular; GUSTO, Global Strategies for Opening Occluded Coronary Arteries; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis; MI, myocardial infarction; NR, not reported; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; RRR, relative risk reduction; TIMI, thrombolysis in myocardial infarction.
| Short name (year published) | Population / subgroup | Experimental group(s) | Comparator | Primary endpoint | Key safety endpoint | Ischaemic stroke | Total stroke |
|-----------------------------|-----------------------|-----------------------|------------|------------------|---------------------|-----------------|--------------|
| **CAPRIE (1996)**<sup>8</sup> | Subgroup of 6452 with PAD | Clopidogrel 75-mg once daily | Aspirin 325-mg once daily | MI, ischaemic stroke or CV death: 3.71% vs. 4.86% per year, RRR = 23.8% [8.9-36.2], P = 0.028 | NR | NR | 81 events vs. 82 events |
| **CHARISMA (2006)**<sup>9</sup> | Subgroup of 3096 with PAD | Clopidogrel 75-mg once daily + aspirin 75 to 162-mg once daily | Aspirin 75 to 162-mg once daily | CV death, MI or stroke: 8.2% vs. 6.8%, HR = 1.25 [1.08-1.44], P = 0.002 | GUSTO severe bleeding: 1.7% vs. 1.7%, HR = 0.97 [0.56-1.66], P = 0.901 | 2.3% vs. 2.4%, HR = 0.97 [0.75-1.25], P = 0.782 | 2.6% vs. 2.9%, HR = 0.94 [0.74-1.20], P = 0.635 |
| **EUCLID (2017)**<sup>14</sup> | 13,885 patients with symptomatic PAD | Ticagrelor 90-mg twice daily for 36 months | Clopidogrel 75-mg once daily for 36 months | CV death, MI or ischaemic stroke: 10.8% vs. 10.6%, HR = 1.02 [0.92-1.13], P = 0.002 | TIMI major bleeding: 1.6% vs. 1.6%, HR = 0.97 [0.62-0.98], P = 0.03 | 1.9% vs. 2.4%, HR = 0.78 [0.62-0.98], P = 0.03 | NR |
| **COMPASS (2017)**<sup>13</sup> | Subgroup of 7470 patients with PAD | Aspirin 100-mg once daily + rivaroxaban 2.5-mg twice daily; or, | Aspirin 100-mg once daily | CV death, MI or stroke: 5% vs. 7%, HR = 0.72 [0.57-0.90], P = 0.0047 | Modified ISTH major bleeding: 3% vs. 2%, HR = 1.61 [1.12-2.31], P = 0.0089 | 1% vs. 2%, HR = 0.54 [0.33-0.87] | NR |
| **VOYAGER PAD (2020)**<sup>15</sup> | 6,564 patients with PAD treated by revascularization | Aspirin 100-mg once daily + rivaroxaban 2.5-mg twice daily | Aspirin 100-mg once daily | ALI, major amputation, MI, ischaemic stroke, CV death: 17.3% vs. 19.9%, HR = 0.85 [0.76-0.96], P = 0.009 | TIMI major bleeding: 2.65% vs. 1.87%, HR = 1.43 [0.97-2.10], P = 0.07 | 2.7% vs. 3.0%, HR = 0.87 [0.63-1.19], P = 0.0043 | NR |

CV, cardiovascular; GUSTO, Global Strategies for Opening Occluded Coronary Arteries; HR, hazard ratio; ISTH, International Society on Thrombosis and Haemostasis; MI, myocardial infarction; NR, not reported; PAD, peripheral artery disease; RRR, relative risk reduction; TIMI, Thrombolysis In Myocardial Infarction.

<sup>8</sup>3-year Kaplan-Meier estimation.
and prasugrel, in those treated with percutaneous coronary intervention (PCI), are superior to clopidogrel. A recent open-label RCT, Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5, demonstrated lower MACE rates with aspirin and prasugrel vs. aspirin and ticagrelor in those with ACS scheduled for invasive evaluation. Similarly, in patients with CCS undergoing PCI, DAPT with aspirin, and clopidogrel for ≥6 months reduces stent thrombosis risk vs. aspirin alone. This regimen is also recommended for 1 month in patients undergoing carotid artery stenting and, with weaker evidence, in those undergoing percutaneous revascularization for LEAD.

After a minor stroke or transient ischaemic attack (TIA), a short period of DAPT offers superior protection from major ischaemic events when compared to aspirin alone, including in patients with CCS or PAD, albeit at the expense of more bleeding.20,21

Considering the longer-term use of DAPT vs. aspirin alone in patients with CCS/PAD, the Clopidogrel for High Atherothrombotic Risk and Ischaemic Stabilization, Management, and Avoidance (CHARISMA) study provided valuable initial data (Tables 1 and 2).9 There was a non-significant reduction in the primary efficacy endpoint of MACE, although there was slightly greater reduction in the secondary efficacy endpoint (primary endpoint events/hospitalization for UA, TIA, or revascularization) [hazard ratio (HR) = 0.92, 95% CI (0.86-1.00); P = 0.04]. Most of the benefit appeared to be stroke-derived [e.g. non-fatal stroke HR = 0.79 (0.64-0.98); P = 0.03], with no significant effect on MI or CV death.

Subsequent RCTs have built an evidence base for long-term DAPT post-ACS. For those at high ischaemic but low bleeding risk who have tolerated ≥1 year of DAPT, continuation beyond 1 year after MI is a recommended option.1 For example, post-MI patients with at least one additional risk-factor benefit from long-term aspirin and reduced-dose ticagrelor (60-mg twice daily) vs. aspirin alone, although underlying bleeding risk should be carefully evaluated. The Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-TIMI 54 (PEGASUS-TIMI 54) study showed MACE reduction in those receiving DAPT vs. SAPT (Table 1).10 There was also a reduction in the risk of stroke. Although TIMI-major bleeding was significantly more frequent with ticagrelor, intracranial haemorrhage, haemorrhagic stroke, or fatal bleeding were not.

Evidence for thienopyridines comes from the DAPT study, which showed 30 vs. 12 months of thienopyridine, alongside aspirin, significantly reduced MACE in prior-MI patients (Table 1).22 Stroke was not significantly reduced, although there was a signal of possible benefit in ischaemic stroke. Unlike MI, the stroke did not occur significantly more frequently in those with a prior MI compared to those without (e.g. total stroke = 0.73% vs. 0.85%, P = 0.51). Current recommendations suggest long-term thienopyridine in prior-MI patients at moderate/high ischaemic risk.1 Prasugrel in combination with aspirin in any situation is contraindicated in those with prior stroke, and aspirin with ticagrelor is similarly not recommended for long-term use in this group.

In patients with CCS but without prior MI, there is little evidence for long-term DAPT. THE effect of ticagrelor on health outcomes in diabetes Mellitus patients Intervention Study (THEMIS) randomized 19 220 aspirin-treated patients with T2DM and CCS, but no MI, to ticagrelor (90-mg reduced to 60-mg twice daily during the course of the trial) or placebo, for a median of 40 months (Table 1).12 Whilst there was lower MACE incidence in those receiving ticagrelor vs. placebo, there was a greater increase in TIMI-major bleeding including intracranial haemorrhage. Ischaemic stroke occurred less frequently when receiving DAPT, as did all stroke. Although

| Ischaemic stroke | Total stroke | Key safety endpoint |
|------------------|-------------|---------------------|
| CHARISMA         | Aspirin + thienopyridine | (GUSTO severe bleeding) |
| DAPT             | Aspirin + ticagrelor       | (GUSTO moderate/severe bleeding) |
| PEGASUS TIMI 54  | Aspirin + Rivaroxaban 2.5 mg BD | (TIMI major bleeding) |
| THEMIS           | Aspirin + Rivaroxaban 2.5 mg BD | (TIMI major bleeding) |
| COMPASS          | Rivaroxaban 5 mg BD        | (Modified ISTH major bleeding) |
| COMPASS          | Rivaroxaban 5 mg BD        | (Modified ISTH major bleeding) |

Figure 3 Forest plots showing HR ± 95% CI for ischaemic stroke, total stroke and the key safety endpoint in RCTs of antithrombotic regimens vs. aspirin monotherapy in patients with CCS/PAD (see Table 1 for trial details). GUSTO, Global Strategies for Opening Occluded Coronary Arteries; ISTH, International Society on Thrombosis and Haemostasis; TIMI, Thrombolysis In Myocardial Infarction.
meeting its primary endpoint, the net clinical benefit has not supported adoption in practice.

**Ticagrelor monotherapy**
Ticagrelor monotherapy has been investigated as an alternative to DAPT in CCS patients treated with PCI, though this is not yet endorsed in recommendations (Supplementary material online).

**Anticoagulant therapy**
Oral anticoagulants (OACs) include vitamin K antagonists (VKAs), e.g., warfarin, and non-VKA oral anticoagulants (NOACs), e.g., the factor Xa (FXa) inhibitors (apixaban, edoxaban, and rivaroxaban) or the thrombin inhibitor dabigatran.23

Anticoagulants in coronary syndromes or peripheral artery disease patients with atrial fibrillation
Atrial fibrillation increases the risk of cardioembolism from the left atrium through disruption in flow and inflammation. Anticoagulation reduces stroke risk in AF by around 60%. The CHA₂DS₂-VASC score is recommended for determining whether an OAC is warranted.1 An OAC is recommended with a score ≥2, and should be considered if ≥1 (excluding females without other criteria).1,2

Non-VKA oral anticoagulants offer superior stroke protection vs. VKA, outside of situations such as moderate/severe mitral stenosis, metallic valve prosthesis, very poor renal function, or non-compliance, in whom there are negative data or therapeutic drug monitoring is necessary. A meta-analysis including 71 683 participants of four phase 3 RCTs (15% with prior MI) showed significantly lower rates of stroke or systemic embolism [HR = 0.81 (0.73–0.91), P < 0.0001] and haemorrhagic stroke [0.49, (0.38–0.64), P < 0.0001] in those receiving a NOAC compared to VKA.23 There were numerically fewer ischaemic strokes in those receiving a NOAC [0.92 (0.83-1.02), P = 0.10]. Different NOACs have never undergone head-to-head clinical outcome-driven RCTs, although observational studies have provided some insight (Supplementary material online). The availability of selective anticoagulants to both FXa inhibitors (andaxenet alfa) and dabigatran (idarucizumab) has increased the safety of these drugs.

There are limited data regarding long-term use of OAC-APT combinations in patients with CCS/PAD and AF, but current recommendations generally advise OAC alone during long-term maintenance therapy.1 Recently, evidence from the Atrial Fibrillation and Ischaemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease (APiRE) trial has largely supported this recommendation (Supplementary material online).

Anticoagulation in patients with coronary syndromes or peripheral artery disease in sinus rhythm
The Warfarin Re-Infarction Study (WARIS) provided the first RCT evidence that an OAC, with or without concurrent aspirin, may offer protection against MACE, including stroke, in CCS/PAD patients without AF, but at the expense of excessive bleeding.24 In the NOAC-era, an evidence-based option for secondary prevention of MACE in high-risk patients with CCS or symptomatic PAD, but without AF, is very-low-dose rivaroxaban in combination with low-dose aspirin. In the Cardiovascular Outcomes for People using Anticoagulation Strategies (COMPASS) study, treatment with aspirin 100-mg once daily plus rivaroxaban 2.5-mg twice daily [low-dose dual antithrombotic therapy (DATT)] led to a significant reduction in the primary endpoint of MACE after a mean follow-up of 23 months, when compared to aspirin 100-mg once daily alone (Tables 1 and 2).13 When compared with aspirin monotherapy, low-dose DATT appeared to have the strongest effect on cardioembolic stroke [HR = 0.40 (0.20–0.78), P = 0.005] or embolic stroke of undetermined source [0.30 (0.12-0.74), P = 0.006]. Benefits of low-dose DATT on stroke prevention appear present in subgroups with CAD or symptomatic PAD, including carotid disease. These data support use of low-dose DATT over aspirin alone in high-risk patients with CCS and/or symptomatic PAD, both in providing general anti-ischaemic protection but also specifically for stroke prevention. This is reflected in the current ESC CCS guidelines,1 whereas the current PAD recommendations were last updated before the COMPASS results were known;2 however, regional bodies such as the European Medicines Agency has approved low-dose DATT in symptomatic PAD as well as high-risk CCS. Recently, the Vascular Outcomes Study of Aspirin Along with Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD (VOYAGER-PAD) study has shown similar findings in a PAD population treated by revascularization (Table 2).15

In patients with PFO and CCS/PAD who have no prior history of stroke, there is no clear evidence that stroke risk is reduced by intensifying antithrombotic therapy beyond that already indicated for the underlying atherothrombotic disease.4

**Other preventive therapies**
Beyond antithrombotic therapy, a wide range of therapies and lifestyle interventions should be incorporated into the routine management of CCS and PAD patients for reducing the risk of stroke (Figure 2 and Supplementary material online).

**Conclusions**
Patients with CCS/PAD are at increased risk of a range of ischaemic events, including stroke, with a significant overlap of risk factors and pathological mechanisms (Figures 1 and 2). Interventions targeting these factors and mechanisms present common therapeutic targets and have been exploited with good results. Overall, a holistic approach to aggressively manage risk factors (Figure 2), including addressing lifestyle aspects, is central to the management of patients with CCS/PAD to prevent the devastating complication of stroke.

**Supplementary material**
Supplementary material is available at European Heart Journal Supplements online.
Funding
WAE Parker is funded by British Heart Foundation Clinical Research Training Fellowship no. FS/18/49/33752. This paper was published as part of a supplement financially supported by the European Society of Cardiology (ESC), Council on Stroke.

Conflict of interest: Disclosures William A. E. Parker has no relevant disclosures. Diana A. Gorog reports honoraria from AstraZeneca, and institutional grants from Bayer and Boehringer-Ingelheim. Tobias Geisler reports personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Pfizer, grants and personal fees from Bayer Healthcare, grants and personal fees from Bristol-Myers Squibb, grants and personal fees from Daiichi Sankyo, grants and personal fees from Eli Lilly and personal fees from Ferrer. Gemma Vilahur reports grants from AstraZeneca, personal fees from AstraZeneca and personal fees from Bayer AG, personal fees from Novartis and personal fees from Medscape. Robert F. Storey reports institutional research grants/support from AstraZeneca, Cytosorbents, GlyCardial Diagnostics and Thromboserin; consultancy fees from Agen, AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, Cytosorbents, GlyCardial Diagnostics, Haemonetics, HengRui, Idorsia, Portola and Thromboserin; and honoraria from AstraZeneca, Bayer, Bristol-Myers Squibb/Pfizer, Intas Pharmaceuticals and Medscape.

References
1. Knuit J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh B, Sivit P, Gildar M, Hasdai D, Hataala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ. ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J 2020;41:407–477.
2. Aboyans V, Ricco J-B, Bartelink M-EL, Björck M, Brodmann M, Cohnert T, Collet JP, Czerny M, De Carlo M, Debux S, Espulina-Klein K, Hakan T, Kownator S, Massollaz L, Naylor AR, Roffi M, Röther J, Snynger M, Tendera M, Tepe G, Vlachopoulos C, Desorais I; ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (EVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816.
3. Parker WA, Storey RF. Novel approaches to P2Y12 Inhibition and aspirin dosing. Platelets 2020;online ahead of print.
4. Pristipino C, Sievert H, D’Ascenzo F, Louis Mas J, Meier B, Achenbach S, Bax JJ. ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (EVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018;39:763–816.
5. Patrono C, Morais J, Baigent C, Collet JP, FitzGerald D, Halvorsen S, Roca B, Siegbahn A, Storey RF, Vilahur G. Antiplatelet agents for the treatment and prevention of coronary atherosclerosis. J Am Coll Cardiol 2017;70:1760–1776.
6. Parker WA, Storey RF. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart 2016;102:783–789.
7. Rajkumar CA, Floyd CN, Ferro A. Antiplatelet therapy as a modulator of stroke aetiology: a meta-analysis. Br J Clin Pharmacol 2015;80:331–341.
8. CAPRIE Steering Committee. A randomised, blinded, trial of clopirogel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348:1329–1339.
9. Bhatt DL, Fox KAA, Hacke W, Berger PB, Black HR, Boden WE, Cucoupo C, Cohen EA, Creager MA, Easton JD, Flatheder MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak-H, Letts J-L, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ; CHARISMA Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–1717.
10. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Ink K, Bengtsson O, Ophus TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinijar N, Nikolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791–1800.
11. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand S-LT, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucow MH, Hermiller J, Dauerman HL, Simon DJ, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi JS, Massaro JM. Twelve or more months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014;371:2155–2166.
12. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstråle W, Leonsson-Zachrison M, Liu Y, Opolski G, Zatezalhchikov D, Ge J, Nicolau LC, Corbalañ C, Cornell JH, Widsinsky P, Leiter LA. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med 2019;381:1309–1320.
13. Elkeilboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakowska O, Diaz R, Alings M, Lonn DA, Anand SS, Widimsky P, Hor M, Avezum A, Piegas LS, Branch KRH, Prosbfleld J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O’Donnelli M, Kakkar AK, Fox KAA, Parkhomenko AN, Erti G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lars F, Cummerford PDR, Torp-Pedersen C, Gzik TJ, Verhamme PB, Vinereaud D, Kim J-H, Tonkin AM, Lewis BS, Felix C, Yusuf K, Steg PG, Metsarainne KP, Cook Bruns N, Mittlewitz F, Chen E, Leong D, Yusuf S. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017;377:1319–1330.
14. Hiatt WR, Fowkes FGR, Heizler G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones W, Blomster J, Millegard M, Reist C, Patel MR. Ticagrelor versus clopidogrel in symptomatic peripheral arterial disease. N Engl J Med 2017;376:32–40.
15. Bonaca MP, Bauersachs RM, Anand SS, Debux ES, Neher MR, Patel MR, Fanelli F, Capell WH, Diao L, Jaeger N, Hess CN, Pap AF, Kittelson JM, Gudz I, Mátys L, Krievins DK, Diaz R, Brodmann M, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR. Rivaroxaban in peripheral arterial disease after revascularization. N Engl J Med 2020;382:1994–2004.
16. Storey RF. Biology and pharmacology of the platelet P2Y12 receptor. Curr Pharm Des 2006;12:1255–1259.
17. Parker WA, Schulte CB, Barwari T, Phoenix F, Pearson SM, Mayr M, Grant PJ, Storey RF, Ajjan RA. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovasc Diabetol 2020;19:3.

Downloaded from https://academic.oup.com/eurheartjsupp/article/22/Supplement_M/M26/6024774 by guest on 09 December 2020
18. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KS. Ticagrelor versus aspirin in acute stroke or transient ischemic attack. *N Engl J Med* 2016;375:35–43.

19. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. *N Engl J Med* 2001;345:494–502.

20. Pan Y, Elm JJ, Li H, Easton JD, Wang Y, Farrant M, Meng X, Kim AS, Zhao X, Meurer WJ, Liu L, Dietrich D, Wang Y, Johnston SC. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: a pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE) and platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trials. *JAMA Neurol* 2019;76:1466.

21. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. *N Engl J Med* 2020;383:207–217.

22. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cullip DE, Cohen DJ, Tanguay JF, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. *J Am Coll Cardiol* 2015;65:2211–2221.

23. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JL, Lewis BS, Parkhomenko A, Yamashita T, Antman E. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet* 2014;383:955-962.

24. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. *N Engl J Med* 2002;347:969-974.